Stay updated on Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record of a Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma, specifically related to the event free survival (EFS) estimation at 2 years from the start of treatment.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:53.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, the inclusion criteria now specify that patients must have a histologically confirmed diagnosis of classical Hodgkin lymphoma and meet other health and treatment history requirements.
    Difference
    39%
    Check dated 2024-05-22T21:18:00.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:33:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.